PenumbraPEN +0.21%88 Return-on-Tangible-Asset is 7.71% as of Mar. 2026, which is 475% above its 10-year median of 1.34. GuruFocus rates PEN with a GF Score™ of 88/100 and a GF Value™ of $332.37 (Fairly Valued). The stock has 1 warning sign investors should review. Among 854 Medical Devices & Instruments companies, Penumbra ranks better than 85.48% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Penumbra's annualizedNet Income for the quarter that ended in Mar. 2026 was $130 Mil. Penumbra's average total tangible assets for the quarter that ended in Mar. 2026 was $1,689 Mil. Therefore, Penumbra's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 7.71%.
The historical rank and industry rank for Penumbra's Return-on-Tangible-Asset or its related term are showing as below:
PEN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2.19 Med: 1.34 Max: 11.79
Current: 10.86
During the past 13 years, Penumbra's highest Return-on-Tangible-Asset was 11.79%. The lowest was -2.19%. And the median was 1.34%.
PEN's Return-on-Tangible-Asset is ranked better than 85.48% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.665
vs PEN: 10.86
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Penumbra Return-on-Tangible-Asset Related Terms
Penumbra Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Penumbra's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PEN vs GMED, PODD, BRKR: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Penumbra's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Penumbra Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Penumbra's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.71% mean?
Penumbra (PEN) has a Return-on-Tangible-Asset of 7.71% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Penumbra and its competitors. This is 475% above median its historical median of 1.34. According to the industry distribution chart, Penumbra ranks #124 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 14.5%.
Is Penumbra's Return-on-Tangible-Asset too high?
Penumbra's current Return-on-Tangible-Asset of 7.71% is 475% above median its 10-year median of 1.34. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.67. Penumbra's value of 7.71% is 1059.4% above this industry median. Based on the distribution chart, Penumbra ranks #124 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Penumbra has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Return-on-Tangible-Asset compare to GMED and PODD?
According to the Medical Devices & Instruments industry distribution chart, Penumbra ranks #124 out of 854 companies for Return-on-Tangible-Asset. This places Penumbra in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.67. Penumbra's value of 7.71% is 1059.4% above this benchmark. While the company's 10-year median is 1.34 vs. the industry median of 0.67, Penumbra has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.67, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Penumbra's current Return-on-Tangible-Asset of 7.71% is 1059.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Penumbra and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Penumbra's current Return-on-Tangible-Asset is 7.71%, which is 475% above median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (PEN) is currently considered Fairly Valued. The stock's GF Value™ is $332.37, compared to a current price of $317.95 — trading 4.3% below its estimated fair value. The current Return-on-Tangible-Asset is 7.71%, which is 475% above median its 10-year median of 1.34 and 1059.4% above the Medical Devices & Instruments industry median of 0.67. Penumbra's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Penumbra (PEN), the current Return-on-Tangible-Asset is 7.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Penumbra (PEN) Overvalued in 2026?
Based on GuruFocus' analysis, Penumbra stock appears to be undervalued.
The current stock price of $317.95 is trading 4.3% below its estimated GF Value™ of $332.37.
GuruFocus considers Penumbra to be Fairly Valued.
Key valuation signals for PEN:
Return-on-Tangible-Asset: 7.71% (475% above median its 10-year median of 1.34)
GF Value™: $332.37 vs. price of $317.95 (4.3% below fair value)
Industry Position: 1059.4% above the Medical Devices & Instruments median (#124 of 854)
No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
88GF Score
Get the complete analysis for PEN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEN has been successfully added to your 
